Efineptakin alfa

BIOLOGICAL5 trials

Conditions

AIDS-Related Kaposi SarcomaCarcinoma, Non-Small-Cell LungDLBCL Arising From Follicular LymphomaHIV InfectionHigh Grade Astrocytic TumorHigh-grade B-cell LymphomaKaposi SarcomaNon Small Cell Lung Cancer

Phase 1

NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery

TerminatedNCT04588038

Hyunseok Kang, MDRecurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma +3

Start: 2021-03-12End: 2025-02-03Updated: 2025-02-14

NT-I7 for Kaposi Sarcoma in Patients With or Without HIV

TerminatedNCT04893018

Fred Hutchinson Cancer CenterAIDS-Related Kaposi Sarcoma, HIV Infection, Kaposi Sarcoma

Start: 2022-05-23End: 2023-12-15Updated: 2024-06-27

Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy

CompletedNCT05075603

NeoImmuneTechDLBCL Arising From Follicular Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma +2

Start: 2021-07-29End: 2025-03-12Updated: 2026-08-10

Phase 2

NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC

TerminatedNCT04984811

NeoImmuneTechCarcinoma, Non-Small-Cell Lung, Nonsmall Cell Lung Cancer, Non Small Cell Lung Cancer +2

Start: 2021-11-15End: 2024-09-19Updated: 2026-06-11

Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

RecruitingNCT05465954

Mayo ClinicHigh Grade Astrocytic Tumor, Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma

Start: 2023-01-24End: 2028-10-15Target: 54Updated: 2026-01-12

Journal of Clinical Oncology2026-05-27

A Phase 1 study evaluating NT-I7 (efineptakin alfa), a long-acting human IL-7, post-tisagenlecleucel (tisa-cel), post-axicabtagene ciloleucel (axi-cel), or post-lisocabtagene maraleucel (liso-cel) in Relapsed/Refractory large B-cell lymphoma

Blood2025-11-03

Phase I study of efineptakin alfa (NT-I7) for the treatment of Kaposi sarcoma

Journal for ImmunoTherapy of Cancer2025-02-015 citations

Efficacy and safety study of neoadjuvant efineptakin alfa (NT-I7) and pembrolizumab in recurrent glioblastoma.

Journal of Clinical Oncology2023-06-013 citations

679 NT-I7 for the treatment of locally recurrent squamous cell carcinoma of head and neck undergoing salvage surgery: a clinical trial in progress

Regular and Young Investigator Award Abstracts2022-11-01

Expansion of CAR-T Cells in Vivo With Long-Acting Interleukin-7 Analog

Oncology Times2022-08-17

Trial in progress: A phase 1b study evaluating the safety, tolerability, and preliminary anti-tumor activity of NT-I7 (efineptakin alfa), a long-acting human IL-7, post-tisagenlecleucel in subjects with relapsed/refractory large B-cell lymphoma.

Journal of Clinical Oncology2022-06-01

Efineptakin alfa

Sponsors

Conditions

Phase 1

Phase 2

Related Papers